Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD), with levels >50 mg/dL affecting 20–30% of the global population. Despite therapeutic ...

Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD), with levels >50 mg/dL affecting 20–30% of the global population.

Lipoprotein(a) as well as two oxidized phospholipids (OxPLs) are all associated with multivessel coronary artery disease detected on angiography and also linked to a higher risk of major adverse ...

Lipoprotein(a), the low-density lipoprotein (LDL)-like particle that is currently the focus of so much enthusiastic research, is significantly more atherogenic than LDL cholesterol, according to a ...

A panel discussion titled “Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?” presented at the American Heart Association (AHA) Scientific Sessions 2023, which convened in ...

Higher lipoprotein(a) (Lp[a]) levels are associated with greater baseline coronary artery plaque burden and faster long-term plaque progression. Studies of Lp(a)-lowering therapies are underway.

Study identifies underutilization of testing, with disparities by race and sex. Elevated lipoprotein(a) [Lp(a)] is a common inherited dyslipidemia linked to increased atherosclerotic cardiovascular ...